Dianhydrogalactitol

Summary

Dianhydrogalactitol (CHEMBL3137322) is a phase-3 clinical-stage small molecule; indicated across 4 conditions including glioblastoma and brain cancer.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 4 conditions
• Clinical trials: 7
• Chemistry: 146.14 Da · C6H10O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3137322
Name	Dianhydrogalactitol
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	15942827
Molecular formula	C6H10O4
Molecular weight	146.14
InChIKey	AAFJXZWCNVJTMK-GUCUJZIJSA-N

SMILES: C1[C@@H](O1)[C@@H]([C@@H]([C@@H]2CO2)O)O

IUPAC name: (1S,2R)-1-[(2S)-oxiran-2-yl]-2-[(2R)-oxiran-2-yl]ethane-1,2-diol

Also known as: Dianhidrogalactitol, Dianhydrogalactitol, Dulcitol diepoxide, NSC-132313, NSC-1323313, VAL-083, DIANHYDROGALACTITOL

Patent coverage: 96 distinct patent families (190 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
glioblastoma	3	MONDO:0018177	EFO:0000519
brain cancer	3	MONDO:0001657	MONDO:0001657
paraganglioma	3	MONDO:0000448	EFO:1000453
ovarian cancer	1	MONDO:0008170	MONDO:0008170

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE1/PHASE2	2
PHASE2	2
PHASE3	1
PHASE2/PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03970447	PHASE2/PHASE3	RECRUITING	A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
NCT03149575	PHASE3	TERMINATED	VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
NCT01478178	PHASE1/PHASE2	COMPLETED	Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
NCT02717962	PHASE2	COMPLETED	Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting
NCT03050736	PHASE2	COMPLETED	Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression
NCT03281681	PHASE1/PHASE2	WITHDRAWN	A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer
NCT03138629	Not specified	NO_LONGER_AVAILABLE	Expanded Access to VAL-083

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).